Ets1 mediates sorafenib resistance by regulating mitochondrial ROS pathway in hepatocellular carcinoma

The incidence and mortality of hepatocellular carcinoma (HCC) are on a rise in the Western countries including US, attributed mostly to late detection. Sorafenib has been the first-line FDA-approved drug for advanced unresectable HCC for almost a decade, but with limited efficacy due to the developm...

Descripción completa

Detalles Bibliográficos
Autores principales: Vishnoi, Kanchan, Ke, Rong, Viswakarma, Navin, Srivastava, Piush, Kumar, Sandeep, Das, Subhasis, Singh, Sunil Kumar, Principe, Daniel R., Rana, Ajay, Rana, Basabi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253325/
https://www.ncbi.nlm.nih.gov/pubmed/35789155
http://dx.doi.org/10.1038/s41419-022-05022-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9253325/
https://www.ncbi.nlm.nih.gov/pubmed/35789155
http://dx.doi.org/10.1038/s41419-022-05022-1

Ejemplares similares